WGS
NASDAQGeneDx Holdings Corp.
News25/Ratings8
News · 26 weeks580%
2025-12-282026-06-21
Mix2490d
- Insider13(54%)
- SEC Filings7(29%)
- Earnings2(8%)
- Other1(4%)
- Leadership1(4%)
Latest news
25 items- SECGeneDx Holdings Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - GeneDx Holdings Corp. (0001818331) (Filer)
- INSIDERCHIEF FINANCIAL OFFICER Feeley Kevin converted options into 7,197 shares and sold $226,597 worth of shares (3,729 units at $60.77), increasing direct ownership by 10% to 39,954 units (SEC Form 4) (tax withholding)4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Stueland Katherine converted options into 18,750 shares and sold $638,104 worth of shares (10,501 units at $60.77), increasing direct ownership by 9% to 104,372 units (SEC Form 4) (withholding tax)4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- INSIDERSEC Form 3 filed by new insider Gardner Mark A3 - GeneDx Holdings Corp. (0001818331) (Issuer)
- SECGeneDx Holdings Corp. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - GeneDx Holdings Corp. (0001818331) (Filer)
- PRGeneDx Names Mark Gardner President to Lead Its Next Phase of Scale and GrowthFormer Quest Diagnostics leader joins to fuel operational and commercial executionGeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced the appointment of Mark Gardner as President, effective June 15, 2026.This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616791724/en/Mark Gardner joins GeneDx as PresidentReporting to Katherine Stueland, Chief Executive Officer, Gardner will lead GeneDx's commercial and operations teams, with a focus on strengthening execution, scaling efficiently and expanding the company's leadership in genomic medicine."GeneDx has built
- INSIDERDirector Casdin Capital, Llc bought $11,109,565 worth of shares (200,000 units at $55.55) (SEC Form 4)4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Feeley Kevin converted options into 717 shares and sold $19,092 worth of shares (369 units at $51.74), increasing direct ownership by 1.00% to 35,290 units (SEC Form 4) to cover taxes4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- PRGeneDx to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceGeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference from June 8-10 in Miami, FL. Management will participate in a fireside chat on Tuesday, June 9, 2026, at 8:00 a.m. ET. A live and archived webcast of the presentation will be available on the "Events" section of the GeneDx investor relations website at ir.genedx.com/news-events/events. About GeneDx GeneDx's (NASDAQ:WGS) mission is to empower everyone to live their healthiest life through genomics. GeneDx combines unmatched clinical expertise, advanced techno
- INSIDERDirector Casdin Capital, Llc bought $21,459,736 worth of shares (500,000 units at $42.92) (SEC Form 4)4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- INSIDERDirector Meister Keith A. bought $13,765,345 worth of shares (351,273 units at $39.19) (SEC Form 4)4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- INSIDERDirector Meister Keith A. bought $46,806,729 worth of shares (1,205,147 units at $38.84) (SEC Form 4)4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- INSIDERSEC Form 4 filed by Director Casdin Capital, Llc4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- SECSEC Form 10-Q filed by GeneDx Holdings Corp.10-Q - GeneDx Holdings Corp. (0001818331) (Filer)
- SECGeneDx Holdings Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - GeneDx Holdings Corp. (0001818331) (Filer)
- PRGeneDx Reports First Quarter 2026 Financial Results and Updates Full-Year OutlookReported total revenue of $102.3 million with 27% year-over-year growth in exome and genome revenue Reported exome and genome volume growth of 34% year-over-year Reported adjusted gross margin(1) of 69% and adjusted net loss(1) of $8.2 million Updating full-year 2026 revenue guidance to $475 to $490 million with exome and genome volume growth of at least 30% Hosting conference call today at 4:30 p.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for the first quarter of 2026. "GeneDx delivered 34% year-over-year volume growth in exome and genome testin
- INSIDERCHIEF EXECUTIVE OFFICER Stueland Katherine converted options into 3,874 shares and sold $141,595 worth of shares (2,172 units at $65.19), increasing direct ownership by 2% to 93,216 units (SEC Form 4) (for tax liability)4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Feeley Kevin converted options into 754 shares and sold $25,555 worth of shares (392 units at $65.19), increasing direct ownership by 1% to 34,942 units (SEC Form 4) to satisfy withholding tax4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- SECSEC Form DEFA14A filed by GeneDx Holdings Corp.DEFA14A - GeneDx Holdings Corp. (0001818331) (Filer)
- SECSEC Form DEF 14A filed by GeneDx Holdings Corp.DEF 14A - GeneDx Holdings Corp. (0001818331) (Filer)
- SECSEC Form 144 filed by GeneDx Holdings Corp.144 - GeneDx Holdings Corp. (0001818331) (Subject)
- PRGeneDx to Report First Quarter 2026 Financial Results on Monday, May 4, 2026GeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the first quarter of 2026 after the market closes on Monday, May 4, 2026. Management will host a conference call that day to discuss first quarter 2026 financial and operating results at 4:30 p.m. Eastern Time. Conference Call Details Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at https://ir.genedx.com/. About GeneDx GeneDx's (NASDAQ:WGS) mission is t
- INSIDERSEC Form 4 filed by Feeley Kevin4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- INSIDERSEC Form 4 filed by Stueland Katherine4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Stueland Katherine sold $1,319,291 worth of shares (17,179 units at $76.80) and converted options into 30,671 shares, increasing direct ownership by 30% to 58,447 units (SEC Form 4)4 - GeneDx Holdings Corp. (0001818331) (Issuer)
WGS FAQ
6 questionsWhere does WGS stock trade?
GeneDx Holdings Corp. (WGS) is listed on NASDAQ.What sector and industry is WGS in?
GeneDx Holdings Corp. operates in the Technology sector, Retail: Computer Software & Peripheral Equipment industry.When did GeneDx Holdings Corp. go public?
GeneDx Holdings Corp. (WGS) completed its IPO in 2020.What are analysts saying about WGS?
GeneDx Holdings Corp. has had 8 recent analyst actions on file. The most recent action was from Wells Fargo: Overweight on 2026-02-09. Recent price targets range from $2100.00 to $4300.00.What companies are similar to WGS?
Notable peers in the same industry include HPE (Hewlett Packard Enterprise Company), SNX (TD SYNNEX Corporation), CDW (CDW Corporation), INGM (Ingram Micro Holding Corporation), CDK (CDK Global Inc.). Compare WGS side-by-side with any of them on Quantisnow.How can I track WGS on Quantisnow?
Quantisnow aggregates GeneDx Holdings Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow WGS to receive live email and push alerts on every new disclosure.